AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “RP1 Approved: A Long Road to a New Option for Patients”
Aug. 07, 2026

RP1 Approved: A Long Road to a New Option for Patients

Featured image for “Patient Webinar: Understanding Your Second-Line Options”
Aug. 07, 2026

Patient Webinar: Understanding Your Second-Line Options

Featured image for “FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma”
Aug. 06, 2026

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

Featured image for “AIM at Melanoma President Samantha Guild Receives SITC’s 2026 Tara Withington Public Service Award”
Aug. 06, 2026

AIM at Melanoma President Samantha Guild Receives SITC’s 2026 Tara Withington Public Service Award

Featured image for “Back to School Considerations for Sun Safety Knowledge and Behaviors”
Aug. 03, 2026

Back to School Considerations for Sun Safety Knowledge and Behaviors

Filter by Tag